Autologous Stem Cell Mobilization and Collection

Hsu, Yen‐Michael S.; Cushing, Melissa M.

doi:10.1016/j.hoc.2016.01.004

Cited by 23 publications

(22 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the former, individuals usually have normal cell counts and the necessary cells are easily obtained; in the latter, the cells being collected—the blasts—are abundant, and the goal of the procedure is their removal rather than their collection. And while autologous peripheral blood stem cell collection in patients with malignancies has been studied, little is known about PBMNC collections for obtaining lymphocytes …”

mentioning

confidence: 99%

Autologous lymphapheresis for the production of chimeric antigen receptor T cells

et al. 2017

View full text Add to dashboard Cite

Background Chimeric antigen receptor (CAR) T cells are a promising new immunotherapy. The first step in manufacturing is to collect autologous CD3+ lymphocytes by apheresis. Patients, however, are often leukopenic or have other disease-related complications. We evaluated the feasibility of collecting adequate numbers of CD3+ cells, risk factors for inadequate collections, and the rate of adverse events. Study Design Apheresis lymphocyte collections from patients participating in 3 CAR T cell clinical trials were reviewed. Collections were performed on the COBE Spectra by experienced nurses, with the goal of obtaining a minimum of 0.6×109 and a target of 2×109 CD3+ cells. Pre-apheresis peripheral blood counts, apheresis parameters, and product cell counts were analyzed. Results Of the 71 collections, 69 (97%) achieved the minimum and 55 (77%) achieved the target. Before apheresis, the 16 patients with yields below the target had significantly lower proportions and absolute numbers of circulating lymphocytes and CD3+ lymphocytes, and higher proportions of circulating blasts and NK cells than those who achieved the target (470 vs. 1340 lymphocytes/μL, p=0.008; 349 vs. 914 CD3+ cells/μL, p=0.001; 17.6% vs. 4.55% blasts, p=0.029). Enrichment of blasts in the product compared to the peripheral blood occurred in 4 patients, including the 2 patients whose collections did not yield the minimum number of CD3+ cells. Apheresis complications occurred in 11 patients (15%), and with one exception, were easily managed in the apheresis clinic. Conclusions In most patients undergoing CAR T cell therapy, leukapheresis is well-tolerated and adequate numbers of CD3+ lymphocytes are collected.

show abstract

mentioning

confidence: 99%

Autologous lymphapheresis for the production of chimeric antigen receptor T cells

et al. 2017

View full text Add to dashboard Cite

show abstract

“…HPCs are collected for the purpose of autologous or allogeneic transplantation in a variety of mostly malignant conditions and some nonmalignant disorders. HPCs are collected from patients and donors after adequate mobilization with growth factors . Donor‐derived and patient‐derived T‐cells are collected for the purpose of novel cellular therapies, such as chimeric antigen receptor T‐cell treatment in mostly autologous cellular collections or for inducing a graft‐versus‐leukemia effect in allogeneic collections.…”

Section: Leukocytapheresis Procedures Typesmentioning

confidence: 99%

“…HPCs are collected from patients and donors after adequate mobilization with growth factors. 1 Donor-derived and patient-derived T-cells are collected for the purpose of novel cellular therapies, such as chimeric antigen receptor T-cell 2 treatment in mostly autologous cellular collections or for inducing a graft-versus-leukemia effect in allogeneic collections. Other cell types of interest in the MNC population are natural killer cells 3 used in some transplant protocols and monocytes used for the preparation of monocyte-derived dendritic cell vaccines.…”

Section: Mononuclear Cell Collectionsmentioning

confidence: 99%

Cellular collection by apheresis

Padmanabhan

2018

Transfusion

View full text Add to dashboard Cite

Cellular collection is an important and increasingly used apheresis procedure. These collections are performed by leukocytapheresis, a procedure involving the removal of a patient's or donor's white blood cells, and are used to collect hematopoietic progenitor cells, specific cell populations (such as T‐lymphocytes), and granulocytes. Hematopoietic progenitor cell apheresis and T‐lymphocyte collection are performed by procedures that enrich for mononuclear cells. Hematopoietic progenitor cells are used for autologous and allogeneic hematopoietic stem cell transplantation, whereas T‐cell collection is being used increasingly in novel cellular therapy approaches and for donor lymphocyte infusions to induce graft‐versus‐leukemia effect. Granulocytes are collected from healthy donors to treat severe sepsis in patients who are refractory to antimicrobial therapies. Less frequently, cellular depletion of leukocytes may be indicated in leukemic patients who have severe hyperleukocytosis resulting in leukoaggregation and decreased tissue perfusion. In these procedures, establishing and maintaining adequate vascular access are critical prerequisites to ensuring a successful procedure. For most types of leukocytapheresis procedures, efforts should be made to ensure that they are performed using peripheral veins, and the use of an intravascular access device should be considered only after it is determined that peripheral access is not feasible or desirable. However, in some settings (such as in patients undergoing autologous hematopoietic stem cell transplantation), intravascular access devices are often used to facilitate both the leukocytapheresis procedure and the subsequent transplant. Here, different types of vascular access approaches used in cellular collections are discussed, and this information is supplemented by the author's experience and practice in areas where published information is limited.

show abstract

“…The Spectra Optia system (Spectra’s next generation), Haemonetics’ MCS + , Fresenius Kabi’s COM.TEC, and Fenwal’s Amicus became more recently available for leukapheresis collection. The Spectra Optia and the Spectra systems have been shown to generate comparable HPSC products, yielding the least amount of red cell contamination, whereas the Amicus system removes fewer platelets from the donor 18, 19, 20, 21…”

Section: Main Textmentioning

confidence: 99%

Genetic Engineering and Manufacturing of Hematopoietic Stem Cells

Wang

Rivière

2017

Molecular Therapy - Methods & Clinical Development

View full text Add to dashboard Cite

The marketing approval of genetically engineered hematopoietic stem cells (HSCs) as the first-line therapy for the treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is a tribute to the substantial progress that has been made regarding HSC engineering in the past decade. Reproducible manufacturing of high-quality, clinical-grade, genetically engineered HSCs is the foundation for broadening the application of this technology. Herein, the current state-of-the-art manufacturing platforms to genetically engineer HSCs as well as the challenges pertaining to production standardization and product characterization are addressed in the context of primary immunodeficiency diseases (PIDs) and other monogenic disorders.

show abstract

Autologous Stem Cell Mobilization and Collection

Cited by 23 publications

References 82 publications

Autologous lymphapheresis for the production of chimeric antigen receptor T cells

Autologous lymphapheresis for the production of chimeric antigen receptor T cells

Cellular collection by apheresis

Genetic Engineering and Manufacturing of Hematopoietic Stem Cells

Contact Info

Product

Resources

About